Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 2
1991 3
1993 1
1995 1
1996 1
1997 1
1998 2
1999 2
2000 2
2001 1
2002 2
2003 8
2004 7
2005 6
2006 15
2007 9
2008 3
2009 8
2010 9
2011 8
2012 12
2013 13
2014 8
2015 6
2016 10
2017 8
2018 6
2019 5
2020 9
2021 15
2022 14
2023 12
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
GRADE Study Research Group; Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Butera NM, Cohen RM, Crandall JP, Kahn SE, Krause-Steinrauf H, Larkin ME, Rasouli N, Tiktin M, Wexler DJ, Younes N. GRADE Study Research Group, et al. Among authors: balasubramanyam a. N Engl J Med. 2022 Sep 22;387(12):1063-1074. doi: 10.1056/NEJMoa2200433. N Engl J Med. 2022. PMID: 36129996 Free PMC article. Clinical Trial.
Remission in Ketosis-Prone Diabetes.
Kikani N, Balasubramanyam A. Kikani N, et al. Among authors: balasubramanyam a. Endocrinol Metab Clin North Am. 2023 Mar;52(1):165-174. doi: 10.1016/j.ecl.2022.06.005. Epub 2022 Nov 4. Endocrinol Metab Clin North Am. 2023. PMID: 36754492 Review.
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Desai MY, Owens A, Geske JB, Wolski K, Saberi S, Wang A, Sherrid M, Cremer PC, Naidu SS, Smedira NG, Schaff H, McErlean E, Sewell C, Balasubramanyam A, Lampl K, Sehnert AJ, Nissen SE. Desai MY, et al. Among authors: balasubramanyam a. Circulation. 2023 Mar 14;147(11):850-863. doi: 10.1161/CIRCULATIONAHA.122.062534. Epub 2022 Nov 6. Circulation. 2023. PMID: 36335531 Clinical Trial.
SYNDROMES OF KETOSIS-PRONE DIABETES.
Balasubramanyam A. Balasubramanyam A. Trans Am Clin Climatol Assoc. 2019;130:145-155. Trans Am Clin Climatol Assoc. 2019. PMID: 31516178 Free PMC article. Review.
Covid-19: A new cause of "provoked" A-β+ Ketosis-Prone Diabetes.
Gaba R, Balasubramanyam A. Gaba R, et al. Among authors: balasubramanyam a. J Diabetes Complications. 2022 Apr;36(4):108147. doi: 10.1016/j.jdiacomp.2022.108147. Epub 2022 Feb 7. J Diabetes Complications. 2022. PMID: 35153127 Free PMC article. No abstract available.
Evaluation and management of ketosis-prone diabetes.
Gaba R, Mehta P, Balasubramanyam A. Gaba R, et al. Among authors: balasubramanyam a. Expert Rev Endocrinol Metab. 2019 Jan;14(1):43-48. doi: 10.1080/17446651.2019.1561270. Epub 2019 Jan 7. Expert Rev Endocrinol Metab. 2019. PMID: 30612498 Review.
Defining and Classifying New Subgroups of Diabetes.
Balasubramanyam A. Balasubramanyam A. Annu Rev Med. 2021 Jan 27;72:63-74. doi: 10.1146/annurev-med-050219-034524. Epub 2020 Oct 16. Annu Rev Med. 2021. PMID: 33064971 Review.
The villain with a thousand faces.
Balasubramanyam A. Balasubramanyam A. J Diabetes Complications. 2014 Jul-Aug;28(4):434-5. doi: 10.1016/j.jdiacomp.2014.02.007. Epub 2014 Feb 18. J Diabetes Complications. 2014. PMID: 24768207 Free PMC article. No abstract available.
195 results